Roche has highlighted new data with its oral treatment for spinal muscular atrophy (SMA) – Evrysdi – showing its benefits when given to pre-symptomatic babies with the rare disease.
Samsung Bioepis and Biogen have claimed the first FDA approval for a biosimilar version of Roche and Novartis' Lucentis (ranibizumab) for leading causes of blindness, raising the prospect o
Shares in Biogen have come under pressure after chief executive Michel Vounatsos admitted that the company is facing a much slower than anticipated rollout of its controversial Alzheimer's
Health insurer Excellus BlueCross BlueShield has said it will not cover treatment with Biogen and Eisai's new Alzheimer's disease drug Aduhelm because it has not been shown to be medically
The FDA's approval of Biogen's Aduhelm for Alzheimer's disease has emboldened Eli Lilly to move forward plans to file its own candidate donanemab later this year, although it acknowledges i
Biogen and partner Eisai have said they will run a large-scale observational study of Alzheimer's drug Aduhelm in the US to build evidence for the drug's efficacy following its controversia